HB-134

N/A

Report date: 2026/03/19 17:11:56

Base Information

Drug NameHB-134
Drug Alias NameHB-134HB134
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > T cell engagers
Mechanisms of ActionAnti-Leukocyte immunoglobulin-like receptor subfamily B member 4Anti-CD3T lymphocytes stimulants +[4] 
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4T cell surface glycoprotein CD3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHuahui Health Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuahui Health Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A